To Find the Best Dose of pVGI.1(VEGF2) to Benefit Angina Patients When Given With
an Experimental Injection Catheter
Basic Study Information
Purpose:
The purpose of this study is to determine the optimum effective dose of recombinant
plasmid
DNA [pVGI.1(VEGF2)] gene therapy administered using an experimental cardiac direct
injection
catheter (Stiletto™) system needed to benefit patients with severe Angina Pectoris.
Location: University of Rochester
Study Contact Information
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search